Please assess the completion status of the following clinical trial:

Trial Title: Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interferon Based Therapies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Is HCV positive (documented by HCV RNA testing at Screening). Chronic hepatitis C is defined as a) Positive for anti-HCV antibody, HCV RNA, or an HCV genotype at least 6 months before screening, and positive for HCV RNA and anti-HCV antibody at the time of screening; or b) Positive for anti-HCV antibody and HCV RNA at the time of screening with a liver biopsy consistent with chronic HCV infection (or a liver biopsy performed before enrollment with evidence of CHC disease, such as the presence of fibrosis), according to Guidance for Industry. Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Agents for Treatment.~* Has previous results from HCV genotype testing. If previous results are not available, such testing should be performed at Screening.~* Has had a liver biopsy or Fibroscan™ within 3 years and the severity of hepatic dysfunction is limited to the following:~  * Metavir Stage 0 to stage 3 fibrosis (according to liver biopsy) or Fibroscan™ results~ * ALT and AST values not exceeding 5 x ULN (Baseline value for each parameter will be calculated as the average of 3 values obtained 7 days apart~ * Normal total bilirubin, and prothrombin time/INR values~* Has elevated liver test results (ALT) at least 1.5 x ULN and not exceeding 5 x ULN (Baseline value for each parameter will be calculated as the average of 3 values obtained 7 days apart~* Is refractory or null responder, intolerable, relapser, or partial responder.~  * Null responder is defined as less than a 2 log10 IU/mL reduction in HCV RNA after 12 weeks of treatment with standard or Peg Interferon/ribavirin or other anti-HCV therapies;~ * Relapser is defined as HCV RNA undetectable (or negative, per site's definition) at the end stage of treatment with a standard or pegylated interferon-based regimen or other anti-HCV therapies, but HCV RNA detectable during post-treatment follow-up;~ * The intolerable is defined as HCV patients who cannot tolerate the side effects of previous interferon-based therapies or other anti-HCV therapies, or who were not suitable for interferon-based therapies or other anti-HCV therapies;~ * Partial responder is defined as achieved more than 2 log10 IU/mL reduction in HCV RNA by Week 12 (± 1 week) during a prior pegIFN/RBV treatment course or other anti-HCV therapies but failed to achieve HCV RNA undetectable at the end stage of treatment.~Exclusion Criteria:~1. Has history of allergy to JKB-122 or related compounds~2. Has human immunodeficiency virus (HIV) or is hepatitis B positive~3. Is with a current diagnosis of cirrhosis, both compensated and uncompensated Child-Pugh A, B or C~4. Has positive urine drug screen at Screening~5. Is currently consuming greater than 30 g of alcohol per day (eg, 2 highballs with 1 shot each, or 2 beers) or has consumed greater than 2 glasses of alcohol per day within 3 months prior to the first screening visit (Day -28)~6. Is being treated with any prescription narcotic drug (including transdermal delivery systems)~7. Has a known or suspected central nervous system disorder that may predispose to seizures or lower the seizure threshold~8. Has unstable and uncontrollable hypertension (\>180/110 mmHg)~9. Has received other therapies for HCV infection (interferon, pegylated interferon, ribavirin, or others) in the last 4 weeks prior to the first screening visit (Day -28)~10. Requires concomitant use of or treatment with opioids or other excluded drugs such as hepatotoxic medications~11. Has received other investigational agents within 30 days prior to the first screening visit (Day -28)~12. Has a disease that would require chronic use of prescription corticosteroids~13. Has either autoimmune or genetic liver disease~14. May be chronically or latently infected with microbial agents other than HCV~15. Has impaired renal function~16. Has BMI\> 30 or BMI \<18~17. If female, pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- JKB-122 5mg (Type: EXPERIMENTAL): 5mg, oral, once daily
- JKB-122 15 mg (Type: EXPERIMENTAL): 15mg, oral, once daily
- JKB-122 35 mg (Type: EXPERIMENTAL): 35mg, oral, once daily
- placebo (Type: PLACEBO_COMPARATOR): comparable capsule, oral, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility